



S4 Fig. Heparin-binding epidermal growth factor–like growth factor (HBEGF)–dependent epidermal growth factor receptor (EGFR) activation in EBC-CR1. (A) The expression of EGFR ligands were measured by reverse transcription polymerase chain reaction (** $p < 0.01$). (B) Addition of HBEGF in EBC-1 was significantly sufficient to acquire resistance to capmatinib (** $p < 0.01$). EBC-1 cell treated with capmatinib±HBEGF for 72 hours. (C) EBC-CR1 with HBEGF was more resistant to EGFR inhibition than without HBEGF (** $p < 0.01$). EBC-CR1 cell treated with afatinib±HBEGF for 72 hours.